Table 2. Correlation of ALDH1 and CD44 expression score with clinicopathological features in endometrial carcinoma.
| ALDH1Low | ALDH1High | CD44- | CD44+ | |||
|---|---|---|---|---|---|---|
| Characteristic | ≤10 | >10 | P value | - | + | P value |
| Patients (no.) | 52 | 40 | 58 | 34 | ||
| Age (years) | 0.370 | 0.049 | ||||
| Range | 31–80 | 33–88 | 31–83 | 33–88 | ||
| Mean±SEM | 54.35±1.40 | 56.65±2.13 | 53.52±1.40 | 58.47±2.20 | ||
| FIGO Stage [no. (%)] | 1.000 | 0.537 | ||||
| I, II | 36 (57.10) | 27 (42.90) | 41 (65.1) | 22 (34.9) | ||
| III | 15 (55.60) | 12 (44.40) | 15 (55.6) | 12 (44.4) | ||
| Nuclear grade [no. (%)] | 0.651 | 0.003 | ||||
| Grade 1 | 24 (61.54) | 15 (38.46) | 32 (82.05) | 7 (17.95) | ||
| Grade 2 | 15 (55.56) | 12 (44.44) | 15 (55.56) | 12 (44.44) | ||
| Grade 3 | 13 (50.00) | 13 (50.00) | 11 (42.31) | 15 (57.69) | ||
| Histological type [no. (%)] | 0.781a | 0.012a | ||||
| Clear cell carcinoma | 3 (50.00) | 3 (50.00) | 1 (16.67) | 5 (83.33) | ||
| Endometrioid Adenocarcinoma | 41 (56.94) | 31 (43.06) | 50 (69.44) | 22 (30.56) | ||
| Mucinous Carcinoma | 2 (100.00) | 0 (0) | 2 (100.00) | 0 (0) | ||
| Serous Carcinoma | 6 (50.00) | 6 (50.00) | 5 (41.67) | 7 (58.33) | ||
| Histological type [no. (%)] | 0.557 | 0.019 | ||||
| Type I EC (EmAC G1 and G2) + MC | 39 (59.1) | 27 (40.9) | 47 (71.2) | 19 (28.8) | ||
| Type II EC (CC, SC) + EmAC G3 | 13 (50.0) | 13 (50.0) | 11 (42.3) | 15 (57.7) |
a Fisher’s exact test.
CC: clear cell carcinoma; EmAC: endometrioid adenocarcinoma; MC: mucinous carcinoma; SC: serous carcinoma.